Us Congress 2023-2024 Regular Session

Us Congress House Bill HB235 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	I
2	2	118THCONGRESS
3	3	1
4	4	STSESSION H. R. 235
5	5	To provide for research and education with respect to triple-negative breast
6	6	cancer, and for other purposes.
7	7	IN THE HOUSE OF REPRESENTATIVES
8	8	JANUARY10, 2023
9	9	Ms. J
10	10	ACKSONLEEintroduced the following bill; which was referred to the
11	11	Committee on Energy and Commerce
12	12	A BILL
13	13	To provide for research and education with respect to triple-
14	14	negative breast cancer, and for other purposes.
15	15	Be it enacted by the Senate and House of Representa-1
16	16	tives of the United States of America in Congress assembled, 2
17	17	SECTION 1. SHORT TITLE. 3
18	18	This Act may be cited as the ‘‘Triple-Negative Breast 4
19	19	Cancer Research and Education Act of 2023’’. 5
20	20	SEC. 2. FINDINGS. 6
21	21	Congress finds as follows: 7
22	22	(1) Breast cancer accounts for 1 in 4 cancer di-8
23	23	agnoses among women in this country. 9
24	24	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H235.IH H235
25	25	kjohnson on DSK79L0C42PROD with BILLS 2
26	26	•HR 235 IH
27	27	(2) The survival rate for breast cancer has in-1
28	28	creased to 90 percent for White women and 78 per-2
29	29	cent for African-American women. 3
30	30	(3) African-American women are more likely to 4
31	31	be diagnosed with larger tumors and more advanced 5
32	32	stages of breast cancer despite a lower incidence 6
33	33	rate. 7
34	34	(4) Early detection for breast cancer increases 8
35	35	survival rates for breast cancer, as evidenced by a 5- 9
36	36	year relative survival rate of 98 percent for breast 10
37	37	cancers that are discovered before the cancer 11
38	38	spreads beyond the breast, compared to 23 percent 12
39	39	for stage IV breast cancers. 13
40	40	(5) Triple-negative breast cancer is a term used 14
41	41	to describe breast cancers whose cells do not have 15
42	42	estrogen receptors and progesterone receptors, and 16
43	43	do not have an excess of the HER2 protein on their 17
44	44	sources. 18
45	45	(6) It is estimated that between 10 and 20 per-19
46	46	cent of female breast cancer patients are diagnosed 20
47	47	with triple-negative breast cancer, and studies indi-21
48	48	cate the prevalence of triple-negative breast cancer is 22
49	49	much higher. 23
50	50	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H235.IH H235
51	51	kjohnson on DSK79L0C42PROD with BILLS 3
52	52	•HR 235 IH
53	53	(7) Triple-negative breast cancer most com-1
54	54	monly affects African-American women, followed by 2
55	55	Hispanic women. 3
56	56	(8) Triple-negative breast cancer is a very ag-4
57	57	gressive form of cancer which affects women under 5
58	58	the age of 50 across all racial and socioeconomic 6
59	59	backgrounds. 7
60	60	(9) African-American women are 3 times more 8
61	61	likely to develop triple-negative breast cancer than 9
62	62	White women. 10
63	63	(10) Triple-negative breast cancer tends to 11
64	64	grow and spread more quickly than most other types 12
65	65	of breast cancer. 13
66	66	(11) Like other forms of breast cancer, triple- 14
67	67	negative breast cancer is treated with surgery, radi-15
68	68	ation therapy, or chemotherapy. 16
69	69	(12) Early-stage detection of triple-negative 17
70	70	breast cancer is the key to survival because the 18
71	71	tumor cells lack certain receptors, and neither hor-19
72	72	mone therapy nor drugs that target these receptors 20
73	73	are effective against these cancers; therefore, early 21
74	74	detection and education is vital. 22
75	75	(13) Current research and available data do not 23
76	76	provide adequate information on— 24
77	77	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H235.IH H235
78	78	kjohnson on DSK79L0C42PROD with BILLS 4
79	79	•HR 235 IH
80	80	(A) the rates of prevalence and incidence 1
81	81	of triple-negative breast cancer in African- 2
82	82	American, Hispanic, and other minority women; 3
83	83	(B) the costs associated with treating tri-4
84	84	ple-negative breast cancer; and 5
85	85	(C) the methods by which triple-negative 6
86	86	breast cancer may be prevented or cured in 7
87	87	these women. 8
88	88	SEC. 3. RESEARCH WITH RESPECT TO TRIPLE-NEGATIVE 9
89	89	BREAST CANCER. 10
90	90	(a) R
91	91	ESEARCH.—The Director of the National Insti-11
92	92	tutes of Health (in this section referred to as the ‘‘Direc-12
93	93	tor of NIH’’) shall expand, intensify, and coordinate pro-13
94	94	grams for the conduct and support of research with re-14
95	95	spect to triple-negative breast cancer. 15
96	96	(b) A
97	97	DMINISTRATION.—The Director of NIH shall 16
98	98	carry out this section through the appropriate institutes, 17
99	99	offices, and centers of the National Institutes of Health, 18
100	100	including the Eunice Kennedy Shriver National Institute 19
101	101	of Child Health and Human Development, the National 20
102	102	Institute of Environmental Health Sciences, the Office of 21
103	103	Research on Women’s Health, and the National Institute 22
104	104	on Minority Health and Health Disparities. 23
105	105	(c) C
106	106	OORDINATION OFACTIVITIES.—The Director of 24
107	107	the Office of Research on Women’s Health shall coordi-25
108	108	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H235.IH H235
109	109	kjohnson on DSK79L0C42PROD with BILLS 5
110	110	•HR 235 IH
111	111	nate activities under this section among the institutes, of-1
112	112	fices, and centers of the National Institutes of Health. 2
113	113	(d) A
114	114	UTHORIZATION OF APPROPRIATIONS.—For the 3
115	115	purpose of carrying out this section, there are authorized 4
116	116	to be appropriated $500,000 for each of the fiscal years 5
117	117	2024 through 2026. 6
118	118	SEC. 4. EDUCATION AND DISSEMINATION OF INFORMATION 7
119	119	WITH RESPECT TO TRIPLE-NEGATIVE 8
120	120	BREAST CANCER. 9
121	121	(a) T
122	122	RIPLE-NEGATIVEBREASTCANCERPUBLIC 10
123	123	E
124	124	DUCATIONPROGRAM.—The Secretary of Health and 11
125	125	Human Services, acting through the Director of the Cen-12
126	126	ters for Disease Control and Prevention, shall develop and 13
127	127	disseminate to the public information regarding triple-neg-14
128	128	ative breast cancer, including information on— 15
129	129	(1) the incidence and prevalence of triple-nega-16
130	130	tive breast cancer among women; 17
131	131	(2) the elevated risk for minority women to de-18
132	132	velop triple-negative breast cancer; and 19
133	133	(3) the availability, as medically appropriate, of 20
134	134	a range of treatment options for symptomatic triple- 21
135	135	negative breast cancer. 22
136	136	(b) D
137	137	ISSEMINATION OF INFORMATION.—The Sec-23
138	138	retary may disseminate information under subsection (a) 24
139	139	directly or through arrangements with nonprofit organiza-25
140	140	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H235.IH H235
141	141	kjohnson on DSK79L0C42PROD with BILLS 6
142	142	•HR 235 IH
143	143	tions, consumer groups, institutions of higher education, 1
144	144	Federal, State, or local agencies, or the media. 2
145	145	(c) A
146	146	UTHORIZATION OF APPROPRIATIONS.—For the 3
147	147	purpose of carrying out this section, there are authorized 4
148	148	to be appropriated such sums as may be necessary for 5
149	149	each of the fiscal years 2024 through 2026. 6
150	150	SEC. 5. INFORMATION TO HEALTH CARE PROVIDERS WITH 7
151	151	RESPECT TO TRIPLE-NEGATIVE BREAST CAN-8
152	152	CER. 9
153	153	(a) D
154	154	ISSEMINATION OF INFORMATION.—The Sec-10
155	155	retary of Health and Human Services, acting through the 11
156	156	Administrator of the Health Resources and Services Ad-12
157	157	ministration, shall develop and disseminate to health care 13
158	158	providers information on triple-negative breast cancer for 14
159	159	the purpose of ensuring that health care providers remain 15
160	160	informed about current information on triple-negative 16
161	161	breast cancer. Such information shall include the elevated 17
162	162	risk for minority women to develop triple-negative breast 18
163	163	cancer and the range of available options for the treatment 19
164	164	of symptomatic triple-negative breast cancer. 20
165	165	(b) A
166	166	UTHORIZATION OF APPROPRIATIONS.—For the 21
167	167	purpose of carrying out this section, there are authorized 22
168	168	to be appropriated such sums as may be necessary for 23
169	169	each of the fiscal years 2024 through 2028. 24
170	170	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H235.IH H235
171	171	kjohnson on DSK79L0C42PROD with BILLS 7
172	172	•HR 235 IH
173	173	SEC. 6. DEFINITION. 1
174	174	In this Act, the term ‘‘minority women’’ means 2
175	175	women who are members of a racial and ethnic minority 3
176	176	group, as defined in section 1707(g) of the Public Health 4
177	177	Service Act (42 U.S.C. 300u–6(g)). 5
178	178	Æ
179	179	VerDate Sep 11 2014 04:45 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6301 E:\BILLS\H235.IH H235
180	180	kjohnson on DSK79L0C42PROD with BILLS